Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07410975 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study aims to evaluate the major pathologic response (MPR) rate of neoadjuvant therapy with sintilimab (PD-1 inhibitor) + IBI310 (anti-CTLA-4 antibody) + chemotherapy, and to assess the efficacy of this treatment strategy in patients with PD-L1-negative stage II - IIIB (excluding N3) NSCLC (according to AJCC 9th) scheduled for surgery.
Trial Details
NCT Number NCT07410975
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Conditions
(from sponsor)		 NSCLC Stage II, NSCLC Stage III
Related terms Carcinoma, Non-Small-Cell Lung, Diabetes Mellitus, Insulin-Dependent, 12
Enrollment 54 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov